Skip to content
Study details
Enrolling now

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

Vanderbilt University Medical Center
NCT IDNCT05288790ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

250

Study length

about 3.4 years

Ages

18–89

Locations

1 site in TN

What this study is about

Researchers are testing whether a pill containing healthy gut bacteria can reduce the risk of heart disease and death in people living with HIV who drink heavily. The trial will examine if this treatment increases the number of good bacteria in the gut, lowers inflammation levels, and reduces the risk of heart disease and death.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Probiotic

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

supplement (Live beneficial bacteria; intended to improve gut flora)

Body systems

Cardiology / Heart, Immune, Infectious